These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30730287)

  • 21. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A joint population pharmacokinetic model to assess the high variability of whole-blood and intracellular tacrolimus in early adult renal transplant recipients.
    Mao J; Zeng F; Qin W; Hu M; Xu L; Cheng F; Zhong M; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112535. PubMed ID: 38908078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
    Hu C; Yin WJ; Li DY; Ding JJ; Zhou LY; Wang JL; Ma RR; Liu K; Zhou G; Zuo XC
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1437-1447. PubMed ID: 30019212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients.
    Kirubakaran R; Hennig S; Maslen B; Day RO; Carland JE; Stocker SL
    Br J Clin Pharmacol; 2022 Feb; 88(4):1751-1772. PubMed ID: 34558092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant.
    Reséndiz-Galván JE; Medellín-Garibay SE; Milán-Segovia RDC; Niño-Moreno PDC; Isordia-Segovia J; Romano-Moreno S
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):303-311. PubMed ID: 30260084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
    Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
    Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.
    Moes DJ; van der Bent SA; Swen JJ; van der Straaten T; Inderson A; Olofsen E; Verspaget HW; Guchelaar HJ; den Hartigh J; van Hoek B
    Eur J Clin Pharmacol; 2016 Feb; 72(2):163-74. PubMed ID: 26521259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.
    Chen X; Wang D; Xu H; Li Z
    J Clin Pharm Ther; 2020 Apr; 45(2):309-317. PubMed ID: 31755126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.
    Li D; Lu W; Zhu JY; Gao J; Lou YQ; Zhang GL
    J Clin Pharm Ther; 2007 Oct; 32(5):505-15. PubMed ID: 17875118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetic Modeling Combined With Machine Learning Approach Improved Tacrolimus Trough Concentration Prediction in Chinese Adult Liver Transplant Recipients.
    Li ZR; Li RD; Niu WJ; Zheng XY; Wang ZX; Zhong MK; Qiu XY
    J Clin Pharmacol; 2023 Mar; 63(3):314-325. PubMed ID: 36097320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients.
    Du Y; Song W; Xiong X; Ge W; Zhu H
    Xenobiotica; 2022 Mar; 52(3):274-283. PubMed ID: 35502774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients.
    Kirubakaran R; Uster DW; Hennig S; Carland JE; Day RO; Wicha SG; Stocker SL
    Br J Clin Pharmacol; 2023 Mar; 89(3):1162-1175. PubMed ID: 36239542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation.
    Andrews LM; Hesselink DA; van Gelder T; Koch BCP; Cornelissen EAM; Brüggemann RJM; van Schaik RHN; de Wildt SN; Cransberg K; de Winter BCM
    Clin Pharmacokinet; 2018 Apr; 57(4):475-489. PubMed ID: 28681225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation.
    Musuamba FT; Mourad M; Haufroid V; Demeyer M; Capron A; Delattre IK; Delaruelle F; Wallemacq P; Verbeeck RK
    J Clin Pharmacol; 2012 Dec; 52(12):1833-43. PubMed ID: 22207766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients.
    Cai X; Song H; Jiao Z; Yang H; Zhu M; Wang C; Wei D; Shi L; Wu B; Chen J
    Eur J Pharm Sci; 2020 Sep; 152():105448. PubMed ID: 32621968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.